Metformin dosing related to renal clearance in outpatients: The MetClear study

Metformin dosing related to renal clearance in outpatients: The MetClear study - The MetClear study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35525

Enrollment

Registered

2009-10-05

Start date

2009-11-18

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus type II

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: diagnosis of diabetes mellitus type II, treatment with metformin

Exclusion criteria

Exclusion criteria: no diabetes mellitus type II, treatment without metformin, participation in other study with blinded study drug

Design outcomes

Primary

Measure	Time frame
To gain a better insight in metformin dose and adjustments to renal clearance.	—

Secondary

Measure	Time frame
Correlation between metformin dose, renal clearance (MDRD), metformin and lactic acid concentration in blood.	—

Countries

Netherlands

Outcome results